Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ladostigil - Avraham Pharmaceuticals

Drug Profile

Ladostigil - Avraham Pharmaceuticals

Alternative Names: Ladostigil hemitartrate; Ladostigil tartrate; TV-3326

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Avraham Pharmaceuticals
  • Class Antidementias; Carbamates; Indans; Neuroprotectants; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mild cognitive impairment
  • Discontinued Alzheimer's disease

Most Recent Events

  • 09 Jul 2019 Phase II development is ongoing for Mild cognitive impairment in Austria, Germany and Israel (Avraham Pharmaceuticals website - July 2019)
  • 09 Jul 2019 Avraham Pharmaceuticals has patent protection for ladostigil in USA and Australia (Avraham Pharmaceuticals website - July 2019)
  • 26 Aug 2015 Phase-II development for Mild cognitive impairment is ongoing in Austria, Germany and Israel
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top